Skin Substitute Billing Fraud Allegations And The Growing Federal Scrutiny Of Florida Physicians

Skin substitute treatments can involve products that cost thousands of dollars, repeated wound applications, and Medicare claims far larger than the professional fee for the physician’s work. That combination has drawn intense federal attention.
In Florida, wound care records, product purchases, application frequency, and reimbursement data are increasingly being examined together to determine whether expensive treatment reflected patient need or a billing strategy built around high-value products.
Investigators may begin with claims data long before speaking with the physician who treated the wound. Once pricing, application volume, and reimbursement patterns begin driving the inquiry, guidance from an experienced Florida healthcare fraud lawyer can help place those numbers against the clinical reasons for treatment and the physician’s actual role in the claim.
Skin Substitute Claims Can Attract Attention Before the Chart Is Reviewed
Federal investigators can sort Medicare claims by product, square centimeters billed, number of applications, physician, and amount paid. A practice using high-cost products more frequently than its peers may stand out immediately.
That data can create the first theory of the case. Repeated applications to the same wound, unusually large quantities, or rapid growth in skin substitute revenue may be treated as evidence that reimbursement drove treatment.
Claims data cannot show the condition of the wound on the date of service. It does not capture failed conservative care, infection risk, vascular issues, tissue loss, or changes between visits. Those facts appear only when the patient-level record is placed beside the billing pattern.
Product Price Can Reshape How Investigators View Medical Judgment
Skin substitutes historically created unusual financial incentives because Medicare reimbursement varied significantly among products. CMS reported that Medicare Part B spending on skin substitutes rose from roughly $252 million in 2019 to more than $10 billion in 2024, driven largely by higher payment rates and launch prices.
A physician’s choice of product may receive scrutiny far beyond ordinary wound care. Investigators can compare the price of the selected product with available alternatives and ask why a more expensive option was used.
Clinical factors may explain the choice. Wound characteristics, prior treatment response, product handling, availability, and the physician’s experience with a particular material can all affect selection. A reimbursement spreadsheet does not establish which considerations actually influenced the decision.
Repeated Applications Can Be Recast as Excessive Treatment
Chronic wounds do not heal on a fixed schedule. Some improve after a small number of applications. Others stall, reopen, or respond unevenly despite continued care.
Federal reviewers may still focus on application frequency. A patient receiving skin substitutes across multiple visits can be portrayed as part of a pattern of unnecessary treatment, particularly when the same product appears repeatedly or utilization exceeds peer norms.
Wound measurements, photographs, tissue condition, response to prior treatment, and changes in the care plan can show what happened between applications and why another treatment was considered appropriate rather than automatic.
The Amount Billed May Not Tell Investigators What Was Actually Used
Skin substitute claims frequently turn on product size and the number of square centimeters reported. Disputes can arise when investigators compare the amount billed with the wound dimensions documented in the chart.
Packaging complicates the picture. A product may come in a size that exceeds the wound area, while treatment may require trimming or use across multiple wounds. Differences between the wound area, the product opened, and the amount reported on the claim can become a central part of the billing dispute.
Procedure notes, product labels, lot information, purchase records, and wound measurements can show what was opened and what was placed on the patient. Without that detail, prosecutors may treat a difference between wound size and billed quantity as deliberate overbilling.
Treatment Records Can Become the Center of the Fraud Allegation
A wound care note written primarily for clinical purposes may later be read as a billing document. Missing measurements, repetitive language, or limited description of prior treatment can give investigators room to argue that the record does not support the application.
Templates can make that problem worse. Repeated phrases across many patients may create the appearance that each treatment followed the same predetermined path even when the wounds differed.
Other records may add what the procedure note leaves out. Nursing documentation, photographs, vascular studies, prior debridement records, hospitalization history, and earlier wound measurements can show how the condition developed and why treatment escalated.
Florida Physicians Are Facing More Aggressive Federal Scrutiny
Federal attention to skin substitutes has accelerated sharply. CMS has described extraordinary growth in Medicare spending and has implemented major payment changes for 2026, including treating skin substitute products as incident-to supplies under the Physician Fee Schedule rather than continuing the prior average-sales-price approach.
Florida has also appeared prominently in recent federal enforcement activity. The Southern District of Florida announced skin substitute and wound care cases as part of the 2026 National Health Care Fraud Takedown, including allegations involving millions of dollars in claims for products that prosecutors contend were unnecessary, never provided, or billed through fraudulent clinic arrangements.
That enforcement environment can draw physicians into investigations even when they controlled only one part of a larger wound care operation. Product vendors, clinic owners, marketers, billing companies, and physicians may each have handled different pieces of the process.
Reimbursement Changes Do Not Rewrite Earlier Clinical Decisions
CMS changed the Medicare payment structure for skin substitutes beginning in 2026. The new approach dramatically reduced payment variation among products and was designed in part to address the spending growth associated with the prior system.
Investigators reviewing older claims may still view high product prices through the lens of today’s enforcement concerns. Older claims have to be read against the reimbursement rules, product availability, and clinical circumstances that existed when the physician treated the wound.
A later payment change does not prove that an earlier treatment choice was fraudulent. The physician’s records from the time of treatment show what was known about the wound, the product selected, and the basis for continued care.
Federal Healthcare Fraud Charges Still Require Knowing Conduct
Skin substitute investigations can move from payment review to criminal allegations when prosecutors believe false claims formed part of a broader scheme. Under 18 U.S.C. § 1347, the government must prove that a person knowingly and willfully executed, or attempted to execute, a scheme to defraud a health care benefit program or obtain its money through false or fraudulent pretenses, representations, or promises.
High reimbursement, repeated applications, or disputed documentation may give prosecutors evidence to investigate. Those facts still do not show what the physician knew about product pricing, coding, claim submission, or the financial arrangements surrounding the practice.
The claim may reflect decisions made across several parts of the operation. A doctor may select the product and determine that another application is clinically appropriate while someone else handles purchasing, unit calculations, coding, or submission to Medicare. That separation can change what the final reimbursement figure actually proves about the physician’s intent.
Responsibility Depends on Who Controlled the Product and the Claim
Wound care operations can involve physicians, nurses, distributors, practice owners, marketers, and outside billing companies. The physician may choose the treatment while others control inventory, purchasing, reimbursement calculations, or claim submission.
Emails, purchase records, contracts, access histories, and payment data can show who selected the product source, who knew its acquisition cost, and who determined what Medicare would be billed. That record may look very different from the claim viewed by itself.
When prosecutors are using pricing and application volume to characterize legitimate wound care as fraud, an experienced Florida healthcare fraud lawyer can place those numbers against the clinical record and the physician’s actual role in the claim.
Contact The Baez Law Firm
If you are facing a federal investigation involving skin substitute products or wound care billing, investigators may already be comparing treatment records with application volume and Medicare reimbursement data. The clinical course of the wound and the physician’s role in the billing process can provide context that raw claim numbers do not.
At The Baez Law Firm, we represent physicians and healthcare professionals facing serious federal healthcare fraud allegations. Contact our firm today to speak with an experienced Florida healthcare fraud lawyer and learn how we can challenge allegations that legitimate wound care decisions were driven by improper billing incentives.
Sources:
- 18 U.S.C. § 1347 – Health Care Fraud
law.cornell.edu/uscode/text/18/1347 - Centers for Medicare & Medicaid Services – Calendar Year 2026 Medicare Physician Fee Schedule Final Rule
cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-medicare-physician-fee-schedule-final-rule-cms-1832-f - Centers for Medicare & Medicaid Services – Billing and Coding: Wound Application of Cellular and/or Tissue Based Products, Lower Extremities
cms.gov/medicare-coverage-database/view/article.aspx?articleid=56696 - S. Attorney’s Office, Southern District of Florida – National Health Care Fraud Takedown Results in 455 Defendants Charged in Connection with Over $6.5 Billion in Alleged Fraud
justice.gov/usao-sdfl/pr/national-health-care-fraud-takedown-results-455-defendants-charged-connection-over-65